genOway Germany GmbH Company Profile

19:12 EDT 21st September 2017 | BioPortfolio

The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1) to reduce high failure rates due to faulty candidate selection and false positives and (2) to identify all the potential candidates among the false negatives. There are thus great potential savings to be realized by making development more efficient. To help make these savings, genOway designs, develops and markets technologies and proprietary innovative genetically modified biological models. These solutions aim to increase the predictability and throughput of research in target validation, drug screening and pharmacological - toxicological studies.


Grundstrasse 16


Phone: 49 (0) 40 40 19 71 00
Fax: 49 (0) 40 43 20 82 61

News Articles [687 Associated News Articles listed on BioPortfolio]

AESKU.GROUP Acquires DST Diagnostische Systeme & Technologien GmbH

Wendelsheim, Germany (PRWEB) June 22, 2017 AESKU.GROUP, an innovation leader in autoimmune diagnostics , is taking over the allergy...

Cosmos Holdings Signs Letter Of Intent To Acquire CC Pharma GmbH A Leading Re-Importer Of EU Pharmaceuticals To Germany

  Life Sciences Jobs   ...

Cheplapharm gets rights to sell Orexigen's Mysimba in Germany, France, and Austria

Orexigen Therapeutics Inc. granted Cheplapharm Arzneimittel GMBH rights to commercialize and distribute the obesity drug Mysimba (naltrexone HCl/bupropion HCl prolonged release) in Germany, France, an...

Novaliq GmbH Conducts A First-In-Class Ocular Neuropathic Pain And Anti-Inflammatory Cannabinoid Drug Development Program In Collaboration With University of Cologne, Germany

  Life Sciences Jobs   ...

Stada bündelt Vertriebsgesellschaften in Deutschland

FRANKFURT (Dow Jones)--Der Arzneimittelkonzern Stada bündelt seine Geschäftsaktivitäten in Deutschland. Die bisher vier Vertriebsgesellschaften Stadavita GmbH, Stada GmbH, cell pharm GmbH und Stad....

New Biometric Driver's License for the Philippines

HAMBURG, Germany, August 30, 2017 /PRNewswire/ -- DERMALOG, the largest German biometrics company, supplies the new driver´s licenses for the Philippines. The new driver´s license system went li...

Innocoll Enters CollaGUARD® Distribution Partnership With Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany

ASHBURN, Va., Feb. 1, 2012 /PRNewswire/ -- Innocoll Inc. announced it has entered into a License and Distribution Agreement with Flynn Pharma Ltd. in the United Kingdom and with Inresa Arzneimitt...

Cosmos Holdings Signs Letter of Intent To Acquire CC Pharma GmbH A Leading Re-importer of EU Pharmaceuticals to Germany

CHICAGO, IL -- (Marketwired) -- 06/23/17 -- Cosmos Holdings, Inc. (the Company) (OTCQB: COSM), an international pharmaceutical company, announced today that it signed a new Letter of Intent (LOI) to ...

PubMed Articles [446 Associated PubMed Articles listed on BioPortfolio]

Biomechanical Characterization of Subclinical Keratoconus Without Topographic or Tomographic Abnormalities.

To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus...

Cyclic and Torsional Fatigue Resistance of Reciprocating Single Files Manufactured by Different Nickel-titanium Alloys.

The aim of this study was to evaluate the cyclic and torsional fatigue resistance of the following reciprocating single-file systems: ProDesign R 25.06 (Easy Equipamentos Odontológicos, Belo Horizont...

Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema.

To examine the reliability of a skin diagnostic device, the SD202 (Courage+Khazaka GmBH, Cologne, Germany), in assessing hydration and erythema of periwound skin and pressure injury-prone areas.

Scleral Thinning Documented by Ultrasound Biomicroscopy after Plaque Therapy for Anterior Ciliary Melanoma.

To evaluate, by ultrasound biomicroscopy (UBM), changes in scleral thickness after ruthenium-106 CCB and CCC plaque (Eckert & Ziegler BE-BIG GmbH, Berlin, Germany) therapy for anterior ciliary melanom...

Antibacterial Efficacy of Octenisept, Alexidine, Chlorhexidine, and Sodium Hypochlorite against Enterococcus faecalis Biofilms.

The purpose of this study was to evaluate the antibacterial effectiveness of Octenisept (OCT; Schülke & Mayr GmBH, Norderstedt, Germany), 1% alexidine (ALX) (Santa Cruz Biotechnology, Inc, Santa Cruz...

Clinical Trials [264 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects

The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics

Telemedical Examination of a Three-Component Oculomotor Testing Battery

The study investigates the feasibility and safety of the telemedical implementation of three diagnostic oculomotor tests using a video-oculography device and an extended teleconferencing s...

The XLIMUS-DES in Very Complex Lesions

Stent delivery failure occurs in 4% of all percutaneous coronary interventions (PCI) and >90% of these failures are due to vessel tortuosity and/or calcification. The XLIMUS eluting corona...

Companies [949 Associated Companies listed on BioPortfolio]

genOway Germany GmbH

The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of t...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...




GYMWATCH GmbH develops advanced fitness technologies and devices. Based in Darmstadt, Germany, near Frankfurt, the company’s first product is the patented GYMWATCH Sensor, wh...

Syntesome GmbH

Syntesome GmbH Munich, Germany active in glycobiology and glycotechnology. Catalog includes about 200 products, mainly glycoconjugates.

More Information about "genOway Germany GmbH" on BioPortfolio

We have published hundreds of genOway Germany GmbH news stories on BioPortfolio along with dozens of genOway Germany GmbH Clinical Trials and PubMed Articles about genOway Germany GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of genOway Germany GmbH Companies in our database. You can also find out about relevant genOway Germany GmbH Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record